Savient Pharmaceuticals, Inc.'s Gout Drug Nod May Trigger Bid War; Abbott Laboratories, Pfizer Inc., Amgen Seen as Likely Suitors

BANGALORE, Sept 21 (Reuters) - Savient Pharma (SVNT.O) investors may be looking at windfall gains as regulatory approval for the firm's gout drug could spark a bidding war valuing Savient at up to double its current stock price.